4basebio PLC (4BB.L), a biotechnology company, on Thursday announced the appointment of Richard Bungay as Chief Financial Officer, effective July 2026.
Bungay succeeds David Roth, who stepped down from the Board earlier this year and remained working with the Company for an orderly handover.
As already announced on February 10, 2026, David Roth stepped down from the company to co-found a new entity with Heikki Lanckriet, the company's founder and former CEO.
Bungay has over 30 years of senior finance and strategic experience in pharma and biotech.
He joins from Sitala Bio Limited, where he helped lead a strategic repositioning, a significant Series A round and execute an in-licencing deal with Fosun Pharma for up to $670 million.
The company also announced board changes effective May 31.
Non-executive Directors Alexander Link and Alan Malus will step down due to other professional commitments. Heikki Lanckriet, non-executive director and former CEO will replace Link as 2invest AG's board appointee.
Cornel Chiriac, representing M&G, will replace Malus, subject to due diligence and regulatory approval.
On the LSE, shares of 4basebio were losing 3.45 percent, trading at 420.00 pence.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.